High-dose group of the test vaccine (60 µg):60µg IN002.5.1

A clinical trial to evaluate the safety and immunogenicity of a heterologous booster dose of SARS-CoV-2 mRNA vaccine IN002.5.1 in healthy adults aged18 to 59 years who completed two-dose homologous vaccination with inactivated vaccine in the past 12-18 months

A clinical trial to evaluate the safety and immunogenicity of a heterologous booster dose of SARS-CoV-2 mRNA vaccine IN002.5.1 in healthy adults aged 60 years or older who completed two-/three-dose homologous vaccination of inactivated vaccine in the =6 months ago